Gholamreza Khademi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gholamreza Khademi has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Majid Sezavar
Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3 shared publications - Maryam Naseri
Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3 shared publications Akram Behrouznia
Resident of Gynecology, Mashhad University of Medical Sciences, Mashhad Iran
1 shared publication- Atiyeh Kaveh
Department of Pediatrics, School of Medicine, Akbar Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
1 shared publication Farah Ashrafzadeh
Mashhad Univ Med Sci, Fac Med, Dept Pediat, Mashhad, Razavi Khorasan, Iran
1 shared publicationFatemeh Resketi
MSc of Jurisprudence and Principles of Islamic Law, Mashhad Iran
1 shared publication
Latest Publications
- Open Access
- 4 March 2026
- Published by Springer Nature in Journal of Anesthesia, Analgesia and Critical Care
- Vol. 6 (1)
Efficacy and safety of dexmedetomidine versus midazolam for sedation in mechanically ventilated pediatric patients: a randomized clinical trial
Aims: The benefits of Dexmedetomidne in sedation of mechanically ventilated pediatric patients are still challenging. In this study, we compared the efficacy and safety of Dexmedetomidine versus Midazolam for achieving deep sedation in pediatric patients receiving mechanical ventilation. Methods: A randomized clinical trial was conducted across three affiliated hospitals during February 2023 until February 2024. Eligible mechanically ventilated children aged 1 month to 18 years were randomized 1:1 to receive either Dexmedetomidine (0.25–1 mcg/kg/h) or midazolam (1–4 mcg/kg/min) for sedation, alongside fentanyl analgesia. Sedation was assessed using the Ramsey Sedation Scale and target scores set on 5–6. Primary outcomes included success rates in achieving target sedation at the beginning of mechanical ventilation; secondary outcomes encompassed hemodynamic adverse effects (hypotension, bradycardia), follow-up assessment of sedation level of successful patients over the next 6 h, mortality rate, mean arterial blood pressures and heart rates (HR) changes, mechanical ventilation and PICU stay duration. Main results: Among 130 eligible patients, 120 were analyzed after exclusions (60 per group). Demographic characteristics were similar between groups. The primary outcome revealed that Dexmedetomidine was less effective than Midazolam in achieving target sedation levels across all ages (p < 0.001). In infants under one year, there was no significant difference in sedation effectiveness between the two medications (P = 0.157). Notably, Dexmedetomidine patients required higher drug doses to maintain sedation over 6 h, while Midazolam patients experienced fewer adjustments (p < 0.001). Hemodynamic complications were significantly less frequent in the Dexmedetomidine group (3.3% vs. 23.3% for hypotension; p < 0.01). However, the two groups did not differ in terms of MAP and HR changes (P = 0.255; P = 0.063). Mortality, mechanical ventilation duration and length of PICU stay were not different between two groups (P = 0.853; P = 0.076; P = 0.082). Conclusion: Dexmedetomidine is inferior to Midazolam for deep sedation during mechanical ventilation in children aged 1 month to 18 years. However, it can be effective in infants under one year of age. Dexmedetomidine presents a lower risk of hemodynamic side effects compared to Midazolam. Trial registration: IRCT20190522043672N3 on February 16, 2023.
- 4 March 2026
- Published by Springer Nature in Journal of Anesthesia, Analgesia and Critical Care
- Vol. 6 (1)
Open AccessEfficacy and safety of dexmedetomidine versus midazolam for sedation in mechanically ventilated pediatric patients: a randomized clinical trial
Aims: The benefits of Dexmedetomidne in sedation of mechanically ventilated pediatric patients are still challenging. In this study, we compared the efficacy and safety of Dexmedetomidine versus Midazolam for achieving deep sedation in pediatric patients receiving mechanical ventilation. Methods: A randomized clinical trial was conducted across three affiliated hospitals during February 2023 until February 2024. Eligible mechanically ventilated children aged 1 month to 18 years were randomized 1:1 to receive either Dexmedetomidine (0.25–1 mcg/kg/h) or midazolam (1–4 mcg/kg/min) for sedation, alongside fentanyl analgesia. Sedation was assessed using the Ramsey Sedation Scale and target scores set on 5–6. Primary outcomes included success rates in achieving target sedation at the beginning of mechanical ventilation; secondary outcomes encompassed hemodynamic adverse effects (hypotension, bradycardia), follow-up assessment of sedation level of successful patients over the next 6 h, mortality rate, mean arterial blood pressures and heart rates (HR) changes, mechanical ventilation and PICU stay duration. Main results: Among 130 eligible patients, 120 were analyzed after exclusions (60 per group). Demographic characteristics were similar between groups. The primary outcome revealed that Dexmedetomidine was less effective than Midazolam in achieving target sedation levels across all ages (p < 0.001). In infants under one year, there was no significant difference in sedation effectiveness between the two medications (P = 0.157). Notably, Dexmedetomidine patients required higher drug doses to maintain sedation over 6 h, while Midazolam patients experienced fewer adjustments (p < 0.001). Hemodynamic complications were significantly less frequent in the Dexmedetomidine group (3.3% vs. 23.3% for hypotension; p < 0.01). However, the two groups did not differ in terms of MAP and HR changes (P = 0.255; P = 0.063). Mortality, mechanical ventilation duration and length of PICU stay were not different between two groups (P = 0.853; P = 0.076; P = 0.082). Conclusion: Dexmedetomidine is inferior to Midazolam for deep sedation during mechanical ventilation in children aged 1 month to 18 years. However, it can be effective in infants under one year of age. Dexmedetomidine presents a lower risk of hemodynamic side effects compared to Midazolam. Trial registration: IRCT20190522043672N3 on February 16, 2023.
- 4 October 2025
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 12 (1) , e43866
Bioinformatics analysis of differentially expressed genes in pediatric multiple sclerosis; identification of key biomarkers and therapeutic targets
Introduction: Pediatric-onset multiple sclerosis (POMS) is a rare but severe form of MS that presents before the age of 18, leading to long-term disability. Despite its clinical significance, the molecular mechanisms driving POMS remain poorly understood. Objectives: This study aims to identify key genes, pathways, and potential therapeutic targets involved in POMS using integrative bioinformatics approaches. Materials and Methods: In this in silico study, gene expression profiles from peripheral blood mononuclear cells of POMS patients and healthy controls were analyzed using the GEO2R platform (GSE203241 dataset). Differentially expressed genes (DEGs) were identified using adjusted P value < 0.05 and a fold change>1.1 or <-1.1. Gene ontology (GO) and pathway enrichment analyses were conducted using BiNGO and Enrichr to explore biological functions and dysregulated pathways. A protein-protein interaction (PPI) network was constructed using STRING (search tool for the retrieval of interacting genes/proteins) and analyzed by Cytoscape with CytoHubba and CytoCluster plugins to identify hub genes and functional modules. Promoter motif analysis was conducted using Tomtom and GoMo to uncover regulatory elements, while DrugBank was utilized to identify potential drug-target interactions. Results: A total of 1101 DEGs were identified, with enrichment in immune response pathways, cytokine signaling, and interferon responses. PPI network analysis revealed 15 hub genes, with MYC, HSP90AA1, JUN, HSPA4, and HIF1A identified by two independent algorithms, highlighting their central role in POMS. CytoCluster analysis uncovered functional modules related to RNA metabolism and vesicle transport. Promoter motif analysis revealed transcription factor binding sites that could influence hub gene expression. Drug-target analysis identified Food and Drug Administration (FDA)-approved and investigational drugs that interact with key hub proteins, offering potential therapeutic candidates. Conclusion: This study provides a comprehensive molecular overview of POMS, identifying critical genes, regulatory elements, and potential drug targets. These findings offer valuable insights into POMS pathogenesis and highlight novel avenues for therapeutic intervention, advancing the prospects for personalized treatment strategies in pediatric MS.
- 4 October 2025
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 12 (1) , e43866
Bioinformatics analysis of differentially expressed genes in pediatric multiple sclerosis; identification of key biomarkers and therapeutic targets
Introduction: Pediatric-onset multiple sclerosis (POMS) is a rare but severe form of MS that presents before the age of 18, leading to long-term disability. Despite its clinical significance, the molecular mechanisms driving POMS remain poorly understood. Objectives: This study aims to identify key genes, pathways, and potential therapeutic targets involved in POMS using integrative bioinformatics approaches. Materials and Methods: In this in silico study, gene expression profiles from peripheral blood mononuclear cells of POMS patients and healthy controls were analyzed using the GEO2R platform (GSE203241 dataset). Differentially expressed genes (DEGs) were identified using adjusted P value < 0.05 and a fold change>1.1 or <-1.1. Gene ontology (GO) and pathway enrichment analyses were conducted using BiNGO and Enrichr to explore biological functions and dysregulated pathways. A protein-protein interaction (PPI) network was constructed using STRING (search tool for the retrieval of interacting genes/proteins) and analyzed by Cytoscape with CytoHubba and CytoCluster plugins to identify hub genes and functional modules. Promoter motif analysis was conducted using Tomtom and GoMo to uncover regulatory elements, while DrugBank was utilized to identify potential drug-target interactions. Results: A total of 1101 DEGs were identified, with enrichment in immune response pathways, cytokine signaling, and interferon responses. PPI network analysis revealed 15 hub genes, with MYC, HSP90AA1, JUN, HSPA4, and HIF1A identified by two independent algorithms, highlighting their central role in POMS. CytoCluster analysis uncovered functional modules related to RNA metabolism and vesicle transport. Promoter motif analysis revealed transcription factor binding sites that could influence hub gene expression. Drug-target analysis identified Food and Drug Administration (FDA)-approved and investigational drugs that interact with key hub proteins, offering potential therapeutic candidates. Conclusion: This study provides a comprehensive molecular overview of POMS, identifying critical genes, regulatory elements, and potential drug targets. These findings offer valuable insights into POMS pathogenesis and highlight novel avenues for therapeutic intervention, advancing the prospects for personalized treatment strategies in pediatric MS.
- 1 January 2022
- Published by Negah Scientific Publisher in Journal of Pediatrics Review
- Vol. 10 (Special ) , 433-438
COVID-19 – Associated Acute Transverse Myelitis in Children: A Case Report and Review of Literature
- 1 January 2022
- Published by Negah Scientific Publisher in Journal of Pediatrics Review
- Vol. 10 (Special ) , 433-438
COVID-19 – Associated Acute Transverse Myelitis in Children: A Case Report and Review of Literature
- Open Access
- 10 June 2020
- Published by Brieflands in Iranian Journal of Pediatrics
- Vol. 30 (4)
Effects of High-Dose Selenium Supplementation on Oxidative Stress and Inflammatory Markers in Critically Ill Children After Gastrointestinal Surgery: A Randomized Clinical Trial
Background: Pediatric observational studies have indicated that most critically ill children have low serum selenium level, which is associated with the increased incidence of multiple organ failure and deteriorated clinical outcomes. Selenium plays a key role in the endogenous antioxidant defense mechanism and inflammatory pathways. Objectives: The present study aimed to assess the effects of high-dose selenium supplementation on the improvement of inflammatory and oxidative stress indices, as well as clinical outcomes, in pediatric patients with severe oxidative stress and inflammation following major gastrointestinal surgeries. Methods: This prospective, single-blind, randomized, parallel group superiority trial was conducted at the pediatric intensive care unit (PICU) of Akbar Pediatric Hospital in Mashhad, Iran in 2019. Patients were assigned to the supplementation (high-dose selenium: 20 µg/kg/d) and control groups (placebo with the recommended dietary allowance doses of selenium) using stratified blocks. Among 72 eligible critically ill children after gastrointestinal surgery, 66 patients completed the study. Inflammatory markers were measured and compared between the groups, including high-sensitivity C-reactive protein (hsCRP), interleukin 1 beta (IL-1β), prooxidant-antioxidant balance (PAB) assay, and clinical outcomes. Data analysis was performed in SPSS version 20 using the intention-to-treat approach. Results: Only 14 patients had optimal serum selenium concentrations before the surgery and PICU admission. At the end of the study, 90.6% of the patients (n = 29) in the intervention group and 100% (n = 34) of those in the placebo group had suboptimal serum selenium levels (< 50 ng/mL). Although supplementation with high-dose selenium decreased the inflammatory markers in the post-surgical critically ill children (-18 mg/mL and -37.5 pg/mL for hsCRP and IL-1β, respectively), the administered dose could not improve the serum glutathione peroxidase (GPx) concentrations as the selenium functional marker, as well as the PAB assay as the single test to assess the balance/imbalance of the oxidants and antioxidants simultaneously. Additionally, clinical outcomes such as infections, length of ICU stay, and 28-day mortality did not improve after the intervention. Conclusions: According to the results, high-dose selenium supplementation (20 µg/kg/d) in the post-surgical critically ill children could improve the serum inflammatory markers. However, the changes were suboptimal with no significant effects of the serum GPx concentrations, antioxidant defense system, and clinical outcomes.
- 10 June 2020
- Published by Brieflands in Iranian Journal of Pediatrics
- Vol. 30 (4)
Open AccessEffects of High-Dose Selenium Supplementation on Oxidative Stress and Inflammatory Markers in Critically Ill Children After Gastrointestinal Surgery: A Randomized Clinical Trial
Background: Pediatric observational studies have indicated that most critically ill children have low serum selenium level, which is associated with the increased incidence of multiple organ failure and deteriorated clinical outcomes. Selenium plays a key role in the endogenous antioxidant defense mechanism and inflammatory pathways. Objectives: The present study aimed to assess the effects of high-dose selenium supplementation on the improvement of inflammatory and oxidative stress indices, as well as clinical outcomes, in pediatric patients with severe oxidative stress and inflammation following major gastrointestinal surgeries. Methods: This prospective, single-blind, randomized, parallel group superiority trial was conducted at the pediatric intensive care unit (PICU) of Akbar Pediatric Hospital in Mashhad, Iran in 2019. Patients were assigned to the supplementation (high-dose selenium: 20 µg/kg/d) and control groups (placebo with the recommended dietary allowance doses of selenium) using stratified blocks. Among 72 eligible critically ill children after gastrointestinal surgery, 66 patients completed the study. Inflammatory markers were measured and compared between the groups, including high-sensitivity C-reactive protein (hsCRP), interleukin 1 beta (IL-1β), prooxidant-antioxidant balance (PAB) assay, and clinical outcomes. Data analysis was performed in SPSS version 20 using the intention-to-treat approach. Results: Only 14 patients had optimal serum selenium concentrations before the surgery and PICU admission. At the end of the study, 90.6% of the patients (n = 29) in the intervention group and 100% (n = 34) of those in the placebo group had suboptimal serum selenium levels (< 50 ng/mL). Although supplementation with high-dose selenium decreased the inflammatory markers in the post-surgical critically ill children (-18 mg/mL and -37.5 pg/mL for hsCRP and IL-1β, respectively), the administered dose could not improve the serum glutathione peroxidase (GPx) concentrations as the selenium functional marker, as well as the PAB assay as the single test to assess the balance/imbalance of the oxidants and antioxidants simultaneously. Additionally, clinical outcomes such as infections, length of ICU stay, and 28-day mortality did not improve after the intervention. Conclusions: According to the results, high-dose selenium supplementation (20 µg/kg/d) in the post-surgical critically ill children could improve the serum inflammatory markers. However, the changes were suboptimal with no significant effects of the serum GPx concentrations, antioxidant defense system, and clinical outcomes.